Table 2 Demographics and transplant details
Characteristic | MRD negative | MRD positive | P |
|---|---|---|---|
N | 1816 | 964 | |
Median follow-up, (months, IQR) | 39.70 (12.89–84.20) | 44.56 (16.07–82.07) | 0.410 |
Median age (years, range, IQR) | 36 (18–70, 26–46) | 38 (18–72, 28–48) | < 0.001 |
Median time dg to HCT (months, range, IQR) | 5.7 (1.9–130, 4.6–8) | 5.6 (2.3–123, 4.5–7.7) | 0.182 |
Median year of HCT (range) | 2012 (2000–2017) | 2012 (2000–2017) | 0.687 |
Median donor age (years, range, IQR, missing) | 34 (4–73, 26–44, 643) | 35 (10–72, 27–44, 293) | 0.080 |
In vivo TCD | 0.221 | ||
No in vivo TCD | 1099 (62%) | 565 (60%) | |
In vivo TCD | 670 (38%) | 381 (40%) | |
Data missing | 47 | 18 | |
Remission status at HCT | 0.518 | ||
CR1 | 1580 (87%) | 847 (88%) | |
CR2 | 236 (13%) | 117 (12%) | |
ALL subtype | < 0.001 | ||
B-ALL Ph-negative | 479 (26%) | 181 (19%) | |
B-ALL Ph-positive | 882 (49%) | 639 (66%) | |
T-ALL | 455 (25%) | 144 (15%) | |
Karnofsky score at HCT | 0.203 | ||
< 80% | 60 (4%) | 41 (5%) | |
> =80% | 1639 (96%) | 861 (95%) | |
Data missing | 117 | 62 | |
Engraftment | 0.459 | ||
Engrafted | 1732 (98%) | 925 (99%) | |
Graft failure | 29 (1.7%) | 12 (1.3%) | |
Data missing | 55 | 27 | |
Source of stem cells | 0.008 | ||
Bone marrow | 409 (23%) | 261 (27%) | |
Blood | 1407 (78%) | 703 (73%) | |
Donor type | 0.268 | ||
Matched sibling | 1041 (57%) | 531 (55%) | |
Unrelated 10/10 match | 575 (32%) | 308 (32%) | |
Unrelated 9/10 match | 200 (11%) | 125 (13%) | |
Conditioning | 0.628 | ||
Chemotherapy-based | 435 (24%) | 223 (23%) | |
TBI containing | 1381 (76%) | 741 (77%) | |
Patient sex | 0.285 | ||
Male | 1097 (60%) | 603 (63%) | |
Female | 717 (40%) | 361 (37%) | |
Data missing | 2 | 0 | |
Donor sex | 0.267 | ||
Male | 1107 (62%) | 606 (64%) | |
Female | 693 (39%) | 346 (36%) | |
Data missing | 16 | 12 | |
Donor–recipient sex mismatch | 0.411 | ||
Female to male | 391 (22%) | 195 (20%) | |
Other | 1409 (78%) | 762 (80%) | |
Data missing | 16 | 7 | |
Patient CMV serology | 0.950 | ||
Negative | 637 (37%) | 342 (37%) | |
Positive | 1090 (63%) | 582 (63%) | |
Data missing | 89 | 40 | |
Donor CMV serology | 0.690 | ||
Negative | 790 (46%) | 414 (45%) | |
Positive | 927 (54%) | 502 (55%) | |
Data missing | 99 | 48 | |
CMV donor/recipient | 0.975 | ||
Negative to negative | 450 (27%) | 239 (27%) | |
Positive to negative | 176 (10%) | 99 (11%) | |
Negative to positive | 317 (19%) | 166 (18%) | |
Positive to positive | 743 (44%) | 398 (44%) | |
Data missing | 130 | 62 | |
HCT-comorbidity index | 0.128 | ||
1 or 2 | 529 (85%) | 271 (81%) | |
> =3 | 92 (15%) | 62 (19%) | |
Data missing | 1195 | 631 | |
GVHD prevention | 0.054 | ||
Cyclosporin | 124 (7%) | 60 (6%) | |
Cyclosporin and MTX | 1247 (70%) | 702 (74%) | |
Cyclosporin and MMF ± MTX | 181 (10%) | 101 (11%) | |
Tacrolimus ± other | 115 (7%) | 41 (4%) | |
Other | 103 (6%) | 41 (4%) | |
Data missing | 46 | 19 | |
Acute GVHD | 0.139 | ||
Grade 0–I | 1156 (67%) | 594 (64%) | |
Grade II–IV | 564 (33%) | 329 (36%) | |
Data missing | 96 | 41 | |
Donor lymphocyte infusion | < 0.001 | ||
None received | 1681 (93%) | 846 (88%) | |
Pre-emptive | 36 (2%) | 48 (5%) | |
After relapse | 97 (5%) | 67 (7%) | |
Data missing | 2 | 3 |